Compare DFH & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFH | GENB |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2020 | N/A |
| Metric | DFH | GENB |
|---|---|---|
| Price | $15.90 | $13.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $26.00 | $23.20 |
| AVG Volume (30 Days) | 568.5K | ★ 829.1K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $4,322,848,000.00 | N/A |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $7.82 | $16.58 |
| P/E Ratio | $133.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $11.00 |
| 52 Week High | $31.10 | $18.18 |
| Indicator | DFH | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 40.20 |
| Support Level | $13.71 | $11.73 |
| Resistance Level | $16.46 | $13.76 |
| Average True Range (ATR) | 0.79 | 0.79 |
| MACD | -0.14 | -0.24 |
| Stochastic Oscillator | 58.39 | 5.08 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.